We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Beckman Coulter and Thermo Fisher to Help HHS Expand US Diagnostic Labs’ COVID-19 Testing Capacity

By LabMedica International staff writers
Posted on 19 Aug 2020
Print article
Illustration
Illustration
The US Department of Health and Human Services (HHS) will make combined investments of USD 6.5 million in two commercial diagnostic laboratories to expand their capacity for conducting up to four million additional SARS-CoV-2 tests per month.

The investments in Aegis Sciences Corporation (Nashville, TN, USA) and Sonic Healthcare USA (Austin, TX, USA) will provide critical laboratory equipment supplied by Beckman Coulter Life Sciences (Brea, CA, USA) and Thermo Fisher Scientific Inc. (Waltham, MA, USA), and increase staffing and infrastructure to allow the US to perform an additional one million tests each week by early October.

In response to HHS investment, Aegis Sciences will rapidly expand its laboratory workforce and begin construction on new laboratory space at its testing facilities to meet its goal of processing more than 60,000 test samples per day beginning in September. With its expanded daily testing capacity, Aegis Sciences has agreed to partner with the Office of the Assistant Secretary for Health to perform testing of samples from select locations with vulnerable populations. These tests will return results in under 48 hours. Sonic Healthcare is collaborating closely with HHS to expeditiously ramp up their testing capacity at eight SARS-CoV-2 testing facilities. HHS will provide access to instrumentation and supplies necessary to rapidly expand the scope and expedite the timeline of their ongoing capacity expansion plans. The new testing capacity will significantly enhance patient access to SARS-CoV-2 diagnostic testing across the US.

Beckman Coulter will provide equipment that will enable laboratories to optimize their workflow, thereby increasing SARS-CoV-2 testing by up to 10,000 tests each day at 10 separate sites totaling an increase of 100,000 per day across the US. Thermo Fisher is supplying HHS with 56 KingFisher Flex extraction and purification systems and 40 QuantStudio 7 Flex Real-time polymerise chain reaction (PCR) tests. Each PCR test can run 384 samples at a time. These 96 systems which are capable of running more than 140,000 samples per day will be placed at the laboratories of Aegis Sciences and Sonic Healthcare around the US.

"We are committed to leveraging every possible opportunity to expand the nation's SARS-CoV-2 testing capacity over the next several months," said Assistant Secretary for Health ADM Brett Giroir, M.D. "For this opportunity, we were able to match available instrumentation and reagents with commercial labs that were ready to immediately expand their services. We are honored to work with these labs and life sciences tools companies to ensure increased access to testing as may be needed this fall."

Related Links:

Aegis Sciences Corporation
Sonic Healthcare USA
Beckman Coulter Life Sciences
Thermo Fisher Scientific Inc.
Gold Member
COVID-19 TEST READER
COVID-19-CHECK-1 EASY READER+
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.